# Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine

> **NCT02079207** · PHASE3 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 767 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** NBP606
- **BIOLOGICAL:** Prodiax-23

## Key facts

- **NCT ID:** NCT02079207
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-10
- **Final completion:** 2015-03
- **Target enrollment:** 767 (ACTUAL)
- **Last updated:** 2016-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02079207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02079207, "Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02079207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*